Prostate Cancer Misdiagnosis Elimination Act of 2016
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 13, 2016)
Prostate Cancer Misdiagnosis Elimination Act of 2016
This bill specifies that, unless the physician ordering a DNA Specimen Provenance Assay (DSPA) test recommends otherwise, a DSPA test furnished with respect to a positive prostate cancer biopsy shall be deemed to be medically necessary for purposes of Medicare.
What just happenedAug 1, 2016
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 13, 2016
- Aug 1, 2016Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 13, 2016IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Jul 13, 2016IntroReferralH11100-A
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jul 13, 2016IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Jul 13, 2016IntroReferralIntro-H
Introduced in House
- Jul 13, 2016IntroReferral1000
Introduced in House